Nine-Month Regimens Incorporating Newer, Repurposed Drugs To Treat Fluoroquinolone-Susceptible, Rifampin-Resistant TB Are On Par With Standard Regimens, Trial Finds

MedPage Today (1/29, Phend) reports, “In the search for shorter, effective, and safe regimens to treat fluoroquinolone-susceptible, rifampin-resistant tuberculosis (TB), three 9-month regimens incorporating newer and repurposed drugs proved on par with standard 18-to-24-months regimens in the multi-arm endTB trial.” Researchers found that “across the five 9-month oral regimens that included various combinations of bedaquiline (Sirturo, B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z), the winning combinations were BLMZ, BCLLfxZ, and BDLLfxZ.” The findings were published in the New England Journal of Medicine.